Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
462-04-006 ISMRM Abstract

DCE-MRI reveals age-related bone-marrow dysfunction in immunocompromised mice

Primary: Preclinical Animal & in vitro MR - Small Animals
Secondary: Preclinical Animal & in vitro MR - Biology, Models, Methods
462-04-006 · Body, Cardiovascular, and Musculoskeletal Systems in Small Animals · Tuesday, 12 May, 2:35 PM–3:30 PM · Digital Posters Row C
Keywords: DSC & DCE Perfusion Hematologic Preclinical Tissue Characterization Aging
Accepted
Ana Gomes 1, Dominique Bonnet2, Bernard Siow1,3
1In Vivo Imaging, The Francis Crick Institute, London, United Kingdom
2Hematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom
3The Francis Crick Institute, London, United Kingdom
Presenting Author: Ana Gomes

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Chuprin J, Buettner H, Seedhom MO et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023 Mar;20(3):192-206. doi: 10.1038/s41571-022-00721-2. [doi]
2. Gomes AL, Gribben J, Siow B et al. Dynamic contrast-enhanced magnetic resonance imaging quantification of leukemia-induced changes in bone marrow vascular function. Haematologica. 2021 Aug 1;106(8):2281-2286. doi: 10.3324/haematol.2020.277269. [doi]
3. Snowden JA, Sánchez-Ortega I, Corbacioglu S et al. European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022 Aug;57(8):1217-1239. doi: 10.1038/s41409-022-01691-w. [doi]
4. Muffly L, Pasquini MC, Martens M et at. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017 Aug 31;130(9):1156-1164. doi: 10.1182/blood-2017-03-772368. [doi]
5. Muffly LS, Kocherginsky M, Stock W et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug;99(8):1373-9. doi: 10.3324/haematol.2014.103655. [doi]
6. Luft T, Dreger P, Radujkovic A. Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation. Bone Marrow Transplant. 2021 Oct;56(10):2326-2335. doi: 10.1038/s41409-021-01390-y. [doi]
7. Stucker S, Chen J, Watt FE, Kusumbe AP. Bone Angiogenesis and Vascular Niche Remodeling in Stress, Aging, and Diseases. Front Cell Dev Biol. 2020 Nov 26;8:602269. doi: 10.3389/fcell.2020.602269. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/462-04-006